Therefore, we speculated that the inhibition of BMP2/SMAD4 signaling, as illustrated in Figure 6, inhibits glioma cell differentiation, leading to glioma cell stemness, which may lead to a poor prognosis in patients with grade II and grade III gliomas. Here, SMAD4 is linked to central nervous system cancer.